Valuation: Genix Pharmaceuticals Corporation

Market Cap 918K 659K 571K 535K 488K 62.87M 933K 6.3M 2.46M 31.47M 2.47M 2.42M 105M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 1.92M 1.38M 1.19M 1.12M 1.02M 131M 1.95M 13.16M 5.14M 65.72M 5.16M 5.05M 219M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
3 months-25.00%
6 months-25.00%
Current year-40.00%
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.04
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.2
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 2018-08-02
President - 2021-05-20
Director of Finance/CFO - 2020-12-13
Director TitleAgeSince
Director/Board Member 57 2018-08-02
Director/Board Member 76 2019-03-10
Director/Board Member 44 2019-09-04
Date Insider Type Main position Quantity % Market Cap.
9/9/25 Option

Chairman

1,000,000 1.6885%
9/9/25 Option

Chairman

1,000,000 1.6885%
9/9/25 Option

Chief Executive Officer

1,000,000 1.6885%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-57.14%-75.00% 660K
-0.62%-0.41%+19.10%+70.62% 48.9B
+1.51%+5.34%+57.99%+122.57% 40.42B
-3.13%+4.12%+22.15%+79.32% 12.6B
-0.29%0.00%-4.13%+16.69% 12.39B
-2.89%-0.76%+30.40%+135.91% 9.07B
-1.77%+5.96%+22.02%+37.63% 7.53B
+0.06%+5.06%+40.35%-13.51% 7.13B
+1.31%+2.70%+12.72%+189.51% 6.78B
+1.45%+4.22%-24.30%+30.37% 5.83B
Average -0.44%+2.49%+11.92%+59.41% 15.06B
Weighted average by Cap. -0.23%+2.37%+27.74%+82.94%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.46 -
Net income -73.2K -52.51K -45.51K -42.66K -38.9K -5.01M -74.37K -502K -196K -2.51M -197K -193K -8.37M -335K -240K -208K -195K -178K -22.94M -340K -2.3M -898K -11.48M -902K -883K -38.3M
Net Debt 804K 577K 500K 469K 427K 55.06M 817K 5.52M 2.15M 27.56M 2.17M 2.12M 91.93M 999K 717K 621K 582K 531K 68.41M 1.02M 6.86M 2.68M 34.25M 2.69M 2.63M 114M
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
  1. Stock Market
  2. Stocks
  3. GENX Stock